Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for High Risk Localized and Locally Advanced Prostate Cancer: A Phase I/Ib Trial

NCT06631521 is registered in ClinicalTrials.gov with AdventHealth as lead sponsor.

NCT NCT06631521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06631521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for High Risk Localized and Locally Advanced Prostate Cancer: A Phase I/Ib Trial
Lead sponsor
AdventHealth
Phase
Phase 1
Overall status
Recruiting
Start date
October 22, 2024
Completion date
June 30, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate ca, prostate cancer (adenocarcinoma), prostate cancer surgery